The Controversy Surrounding Legalization of Medical Marijuana in Spain

Regulations by 2FIRSTS.ai
May.22.2024
The Controversy Surrounding Legalization of Medical Marijuana in Spain
Madrid President Isabel Díaz Ayuso opposes cannabis legalization, sparking conflict with her party's mayors supporting medical marijuana cultivation.

According to a report in the Spanish newspaper Publico on May 21st, the president of the Madrid region, Isabel Diaz Ayuso, has recently vehemently opposed any regulations regarding marijuana, including for medical purposes, as she believes its legalization is "extremely absurd". However, this stance conflicts with the position of mayors from her political party across Spain, who support companies growing marijuana for therapeutic purposes in their municipalities, with approval from the Spanish Agency for Medicines and Health Products (AEMPS).

 

Isabel Díaz Ayuso, President of the Madrid Community and the People's Party, believes that linking marijuana to health and healing is inappropriate, as teenagers are "ending the trend of associating drugs with nature and positivity.

 

However, in a contradictory situation, Isabelle faces opposition from mayors across Spain as she begins production of thousands of kilograms of medical marijuana and fully exports it to other countries where its use is already regulated in the political, informational, and cultural battle against cannabis.

 

The largest medical cannabis production company in Spain, Linneo Health, which has already started producing up to 25,000 tons of cannabis annually, is receiving strong support from the mayor. Linneo Health has planned to cultivate and process cannabis on 47 hectares of land in Murcia, and has already invested 35 million euros in fixed equipment, employing 120 permanent staff.

 

In addition, Mayor Juan Manuel González also visited the facilities of Medicinal Flowers, a company in the province of Verva that has begun production of medical marijuana.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

TPB Q4 FY2025 Revenue Rises 29% to $121 Million; Modern Oral Business Up 266% Year Over Year
TPB Q4 FY2025 Revenue Rises 29% to $121 Million; Modern Oral Business Up 266% Year Over Year
Turning Point Brands, a U.S. nicotine and tobacco-related consumer products company, reported its fiscal 2025 fourth-quarter results: quarterly revenue was $121 million, up 29% year over year; adjusted EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) was $30 million, up 14%. Net revenue from modern oral nicotine products was $41.3 million, up 266% year over year.
Mar.03 by 2FIRSTS.ai
WHO warns Europe will remain the world’s biggest tobacco consumer by 2030 as vaping fuels youth uptake
WHO warns Europe will remain the world’s biggest tobacco consumer by 2030 as vaping fuels youth uptake
According to Euronews, the World Health Organization (WHO) says its European Region—53 countries across Europe and Central Asia—is projected to remain the world’s largest tobacco consumer by 2030. While overall tobacco use is declining, e-cigarettes and flavoured nicotine products are capturing a new generation.
Feb.27 by 2FIRSTS.ai
Guam checks 277 eligible retailers in 2025; eight found selling tobacco or disposable vapes to minors aged 16–20
Guam checks 277 eligible retailers in 2025; eight found selling tobacco or disposable vapes to minors aged 16–20
he Guam Behavioral Health and Wellness Center said that out of 277 eligible tobacco retailers inspected in 2025, eight were found selling tobacco or disposable e-cigarettes or vapes to minors aged 16–20, and one retailer failed to display the required “No Sale Under 21” prohibition sign.
Jan.05 by 2FIRSTS.ai
Charlie’s Holdings Signs Licensing Agreement with IKE Tech to Commercialize Age-Gated Vape Technology in the U.S.
Charlie’s Holdings Signs Licensing Agreement with IKE Tech to Commercialize Age-Gated Vape Technology in the U.S.
Charlie’s Holdings has signed a licensing agreement with IKE Tech to commercialize an age-gated vape activation system in the U.S. The technology combines biometric authentication, BLE hardware, and a mobile app for continuous device-level age verification. The company plans to test-market the system with SBX nicotine analogue products this spring and may later apply it to PACHA-branded ENDS.
News
Jan.06
China Business Journal Reports: Multiple New E-Cigarette Policies Enter Public Consultation Phase in China, Covering Capacity Control and Credit Management
China Business Journal Reports: Multiple New E-Cigarette Policies Enter Public Consultation Phase in China, Covering Capacity Control and Credit Management
China Business Journal, citing a review of policy documents released by the State Tobacco Monopoly Administration in early 2026, said China’s latest e-cigarette rules target credit-based regulation, capacity controls and national standards revisions.Alan Zhao, co-founder of 2Firsts, said tighter oversight will speed consolidation, curb noncompliance and reduce destructive competition.
Jan.12 by 2FIRSTS.ai
PMI Launches Mass Production of ZYN at $600M Aurora Manufacturing Hub
PMI Launches Mass Production of ZYN at $600M Aurora Manufacturing Hub
Philip Morris International (PMI), through its subsidiary Swedish Match, has started large-scale production at a 600,000-square-foot ZYN nicotine pouch facility in Aurora, Colorado. The $600 million investment makes the site one of three ZYN manufacturing plants in the United States and the company’s second U.S. facility after Owensboro, Kentucky.
PMI
Feb.21